Picture supply: Getty Photos
kromek group (LSE: KMK) is goal-Listed a 107p penny inventory with a market capitalization of £72.6m. The UK-based group develops radiation detection tools for medical imaging, nuclear services and safety inspections.
Primarily serving the home and US markets, it primarily provides cadmium zinc telluride primarily based detectors.
This can be a comparatively area of interest market, which can have some benefits and a few drawbacks. Though it’s unlikely to face robust competitors, altering circumstances may trigger demand for its merchandise to say no sharply.
However to this point it appears to be working very nicely. Let’s take a more in-depth look.
Excessive development expectations
The share value has risen 103% over the previous 12 months, pushed primarily by robust first-half outcomes for the six months to 31 October 2025.
And analysts following the inventory do not assume it is over. They anticipate additional development, with an formidable 12-month goal of a rise of twenty-two.5p, or 106%.
However is it lifelike to anticipate the inventory value to double once more by subsequent April?
Earlier than I get too excited, I made a decision to take a more in-depth look.
there’s a demand
What I like about Chromek is that it really has fairly first rate earnings visibility for a penny inventory. The corporate has a powerful near-term income pipeline, with offers valued at over $20 million in 2026.
This momentum is being pushed by gross sales enlargement in 39 new international locations in Europe, the Center East and Asia.
Within the first half of 2026, revenues have been reported to have reached £15m, up from £3.7m, with administration concentrating on £60m by 2030. That is an formidable objective, however is it supported by proof of common demand?
These notable order and contract wins appear to counsel that:
- Orders price 4.8 million kilos worldwide.
- $37.5 million contract with Siemens Healthineers;
- a £1.7 million, four-year radiological and nuclear detection framework with the UK Ministry of Defence.
- Extra nuclear safety orders price £2.9m from the UK/Europe, US, Japan and Canada.
- Multi-year biosecurity agreements in the USA.
Which means it is a worthwhile, rising enterprise and seems to be in excessive demand. What’s the issue?
danger
Microcap shares have at all times confronted greater dangers than bigger firms, and Comec is used to that. Provide chain points and reliance on debt are key challenges that the Group has struggled with prior to now.
The corporate nonetheless has money owed of £4.62m and desires to take care of excessive money move to stay in enterprise. A major contract loss or order delay may throw it off monitor. Moreover, penny shares are thinly traded, rising liquidity danger for shareholders.
Nonetheless, with fairness of £56.88m and return on fairness (ROE) of 25%, we will not say it is struggling.
my verdict
Penny shares at all times require a bit of extra religion than large-cap shares, and the potential for greater rewards comes with better danger. Assessing them usually looks like attempting to see in the dead of night. Nevertheless, within the case of Kromek Group, its anticipated value will increase are backed by real-world use circumstances and steady demand.
Along with regular orders for medical imaging, demand is prone to enhance because of the rising menace of nuclear instability within the Center East.
Like several microcap, this isn’t one thing it is best to go all-in on. However given the rising demand and promising forecast, it is price contemplating as a small allocation.